The CPMGAH22–05 trial tested second-line therapy and beyond in patients with advanced HER2-positive GC, and chemo-free margetuximab plus pembrolizumab led to meaningful outcomes [56]. This evidence concerns the gene ERBB2 and gastric cancer.